FDA warning: some patients cannot process Plavix

Mar 12, 2010 By MATTHEW PERRONE , AP Business Writer
In this July 28, 2006 file photo, blood thinner medication Plavix is shown in New York. The Food and Drug Administration is adding its strongest warning to the label for Plavix Friday, March 12, 2010, after reports that some patients cannot process the blood thinning drug.(AP Photo/Mark Lennihan, file)

(AP) -- The Food and Drug Administration is adding its strongest warning to the label for Plavix, cautioning that some patients do not respond to the blockbuster blood thinner.

The FDA said in a statement Friday that certain patients with a cannot metabolize the drug, putting them at increased risk for heart attack and stroke.

Patients can determine if they are "poor metabolizers" by taking a genetic test. The FDA recommends these patients use other blood thinners, such as .

The FDA added similar language to Plavix's label in November, but the new warning appears within a black box, the FDA's most severe safety labeling.

Plavix is prescribed to patients to prevent dangerous blood clots, which can cause , stroke and death.

With genetic tests costing around $500, experts say it's unlikely such testing will become standard for patients taking Plavix.

"I think based on this people will do more , but I think it's premature to say that everyone who gets Plavix needs to be tested," said Dr. Louis Teichholz, head of cardiology at Hackensack University Medical Center.

Teichholz said the black box warning on Plavix could push more doctors to prescribe Effient, a competing blood thinner launched by Eli Lilly & Co. last summer.

In order to work effectively, Plavix must be broken down by a particular liver enzyme. But FDA says 2 to 14 percent of people in the U.S. have low levels of the enzyme, preventing them from successfully processing Plavix. The likelihood of being a non-responder varies by race, according to the FDA.

"Patients should not stop taking Plavix unless told to do so by their health care professional," the agency said in an online statement. "They should talk with their health care professional if they have any concerns about Plavix, or to find out if they should be tested for being a poor metabolizer."

Using a higher dose of Plavix can increase blood thinning in non-responsive patients, according to the new label, though higher doses have not been cleared by the FDA.

Plavix is marketed by Sanofi-Aventis and Bristol-Myers Squibb. With global sales of $8.6 billion in 2008, it was the world's second-best selling drug behind Pfizer's cholesterol drug Lipitor.

A spokeswoman for New York-based Bristol-Myers said the company would add the new labeling to bottles of Plavix over the next two months.

"The revisions to the prescribing information for Plavix reflect the companies' ongoing research in collaboration with the FDA," said Laura Hortas.

In November, the FDA warned that taking stomach-soothing drugs like Prilosec and Nexium alongside Plavix could cut the blood-thinner's effect in half. Regulators said the key ingredient in the heartburn medications blocks the same liver enzyme needed to break down , muting the drug's full effect.

Shares of Bristol-Myers Squibb Co. fell 7 cents to $25.89. Shares of Sanofi-Aventis fell 30 cents to $37.89.

Explore further: FDA OKs Merck tablet to reduce ragweed allergies

4.3 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

FDA says heartburn drugs can interfere with Plavix

Nov 17, 2009

(AP) -- Federal health officials said Tuesday a popular variety of heartburn medications can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack ...

FDA clears Eli Lilly's blood thinner Effient

Jul 10, 2009

(AP) -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its bleeding risks.

Study: Plavix plus aspirin helps prevent strokes

Mar 31, 2009

(AP) -- Taking the blood thinner Plavix along with aspirin helped prevent strokes and heart attacks in people with a common heartbeat abnormality that puts them at high risk of these problems, doctors reported Tuesday.

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (1) Mar 12, 2010
" The likelihood of being a non-responder varies by race, according to the FDA."

So which race is most likely to not respond?

More news stories

Treating depression in Parkinson's patients

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's ...

Impact glass stores biodata for millions of years

(Phys.org) —Bits of plant life encapsulated in molten glass by asteroid and comet impacts millions of years ago give geologists information about climate and life forms on the ancient Earth. Scientists ...